At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Romiplostimbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
In Brief
A Phase 2 clinical trial evaluating Romiplostim for Idiopathic Thrombocytopenic Purpura. Completed, enrolled 75 participants across 48 sites in 9 countries.
Detailed Summary
The purpose of this study is to describe the number of months with a platelet response over a 12 month treatment period and to describe ITP remission rates in adults with ITP receiving romiplostim.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Thrombocytopenic Purpura
CountriesAustralia, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartNov 2010
Primary CompletionSep 2013
Study CompletionDec 2013
TodayJul 2026
First PostedJun 14, 2010
Enrollment StartNov 30, 2010
Primary CompletionSep 20, 2013
Study CompletionDec 26, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.1 years ago
Interventions
Romiplostimbiological
Romiplostim will be administered weekly by subcutaneous injection